Processing

Please wait...

Settings

Settings

Goto Application

1. MXPA/a/2000/010245 - CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF

Office
Mexico
Application Number PA/a/2000/010245
Application Date 19.10.2000
Publication Number PA/a/2000/010245
Publication Date 09.05.2002
Publication Kind A
IPC
C12N 5/10
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
10Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
Applicants MICROMET AG
Inventors KUFER, Peter
LUTTERBüSE, Ralf
BARGOU, Ralf
LöFFLER, Anja
BERND DÖRKEN
GERT RIETHMÜLLER
Agents MIGUEL A. ESTEVA*
Priority Data 98107269.7 21.04.1998 EP
Title
(EN) CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF
(ES) POLIPEPTIDOS INNOVADORES CD19 X CD3 ESPECIFICOS Y SU UTILIZACION
Abstract
(EN) Described are novel single-chain multifunctional polypeptides comprising at least two binding sites specific for the CD19 and CD3 antigen, respectively. Further provided are polypeptides, wherein the above-described polypeptide comprises at least one further domain, preferably of pre-determined function. Furthermore, polynucleotides encoding said polypeptides as well as to vectors comprising said polynucleotides and host cells transformed therewith and their use in the production of said polypeptides are described, In addition, compositions, preferably pharmaceutical and diagnostic compositions are provided comprising any of the afore-described polypeptides, polynucleotides or vectors. Described is also the use of the afore-mentioned polypeptides, polynucleotides and vectors for the preparation of pharmaceutical compositions for immunotherapy, preferably against B-cell malignancies such as non-Hodgkin lymphoma.
(ES) La presente invención se refiere a los polipéptidos multifuncionales de cadena simple innovadores que comprenden por lo menos dos sitios aglomerantes específicos para el antígeno CD19 y CD3, respectivamente. Además se proveen polipéptidos donde el polipéptido antes descrito comprende por lo menos un dominio adicional, preferentemente de función predeterminada. Además, se describen los polinucleótidos y células huésped transformadas ahíy su utilización en la producción de estos polipéptidos. Se describe también la utilización de los polipéptidos, los polinucleótidos y los vectores antes mencionados para la preparación de composiciones farmacéuticas para la inmunoterapia, preferentemente malignidades de la célula B como el linfoma que no es del tipo Hodgkin.
Related patent documents
ININ/PCT/2000/544/CHEThis application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
HRP20000714AThis application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
TR2000/03087This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
ZA200005866This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
NO20005296This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.